Navigation Links
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
Date:5/18/2009

DUBLIN, May 19 /PRNewswire/ --

- Completed Series B Total Stands at EUR21.3 m

Opsona Therapeutics, a biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, today announced that Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3 million to the Series B financing announced in February this year, bringing the total round to EUR21.3 million. The new investors join Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba-Kernel in completing the round, which will enable Opsona to further expand its clinical development pipeline.

Proceeds will support the advancement of Opsona's clinical trials targeting inflammatory diseases such as rheumatoid arthritis, lupus and solid organ transplant rejection. It will also be used to improve Opsona's capability to clinically evaluate novel compounds for in-licensing aimed at treating autoimmune and inflammatory diseases.

Commenting on the announcement, Mark Heffernan, Chief Executive Officer of Opsona Therapeutics, said: "We are delighted by the calibre of investors who have supported our Series B financing. The investment by Roche Venture Fund is a further endorsement of Opsona's approach to targeting the innate immune system, and the continued support of Enterprise Ireland demonstrates their commitment to investment in high-potential companies. This completed

Series B round of EUR21.3 million places Opsona in a strong financial position, which will enable us to continue to achieve our clinical and operational goals over the next three years."

"Roche is excited about investing in Opsona," said Carole Nuechterlein, Head of the Roche Venture Fund. "Opsona's scientific founder, Professor Luke O'Neill of Trinity College Dublin, is world renowned for his expertise in Toll-like receptors
'/>"/>

SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes
2. Codexis R&D Productivity Panels Also Used By Roche
3. Roche Madison Moves to New Facility
4. BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services
5. Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
6. Roche Completes Tender Offer for Genentech
7. Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
8. SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests
9. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
10. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
11. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Sigma-Aldrich(TM) (Nasdaq:,SIAL), a life science company dedicated ... world,s researchers, and Oxford,BioMedica (LSE: OXB), a leading ... key order confirming the strength and validity of,intellectual ... in,the research field to Sigma-Aldrich. The ruling was ...
... antibody uses novel approach to "de-cloak" cancers -, ... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... new findings have been,presented from its Trop-2 and ... Trop-2 and CD59 abstracts at the AACR press,conference ...
... Novocell, Inc., a leading stem cell,engineering company, today ... Vice President, Clinical & Regulatory Affairs of,Amylin Pharmaceuticals, ... Kolterman joined Amylin in 1992 and has served ... until present and as Senior,Vice President, Regulatory Affairs ...
Cached Biology Technology:Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors 2
(Date:7/10/2014)... business incubator, received a $1.4 million federal grant to ... staunch bleeding during brain surgery. , Surgeons can spray ... bio-polymer solutions in the gel will cohere and control ... The gel can shorten an intracranial surgery by 30- ... the patient,s skull to be open and less anesthesia, ...
(Date:7/10/2014)... State University have developed a small, portable and ... over the world better understand the radiation around them, ... poses a health risk. , The device was developed ... incident in Fukushima, Japan, in 2011, when many regional ... being exposed to and whether their homes, food, environment ...
(Date:7/10/2014)... Cancer Research Centre (CNIO) Macromolecular Crystallography Group has ... called BuD to DNA in order to redirect ... researcher who led the study, says the discovery: ... instructions contained in the genome to treat genetic ... is published in the journal Acta Crystallographica, ...
Breaking Biology News(10 mins):A start-up at NJIT develops bleeding-control gel for brain surgery 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3CNIO scientists develop technology to redirect proteins towards specific areas of the genome 2
... able to survive the harsh environs of Mars long ... to research published in the April 2010 issue of ... The search for life on Mars remains a stated ... To preserve the pristine environments, the bioloads on spacecraft ...
... social insects, but paper wasps and honey bees organize their ... report that despite their differences, these insects rely on the ... The study appears in the Proceedings of the Royal ... wasps are separated by more than 100 million years of ...
... Albuquerque, N.M. A new supercomputer that more quickly ... the sun, wind and other renewable resources is now ... 180-teraflop computing platform, is a collaboration between Sandia and ... dedicated the supercomputer earlier this month, along with representatives ...
Cached Biology News:Paper wasps and honey bees share a genetic toolkit 2Defense-scale supercomputing comes to alternative energy research 2
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... Analyst Software has been optimized for the ... allow the software to quickly and accurately ... well of an ELISA plate or each ... Software has been customized to incorporate standard ...
... An easy-to-use solution that enables fully automated ... 400 Hybridization Station has been designed to ... the throughput necessary to perform a wide ... performed in the range 485C; denaturations of ...
The Piezo Power MicroDissection (PPMD) system is designed for rapid isolation of single cells or small cell areas...
Biology Products: